Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechnology: Archive
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
BMYPositive Net Change MRNANegative Net Change SYRSPositive Net Change AMLXPositive Net Change
biotechnology biotechs pharmaceuticals
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
by Zacks Equity Research
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
SNYPositive Net Change AZNPositive Net Change RHHBYPositive Net Change NRIXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
by Zacks Equity Research
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ANABNegative Net Change
biotechnology
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
by Zacks Equity Research
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
BMYPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change
biotechnology medical pharmaceuticals
Intellicheck Mobilisa, Inc. (IDN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IDNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
by Zacks Equity Research
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
ADMAPositive Net Change FGENNegative Net Change EYENNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
by Zacks Equity Research
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
by Zacks Equity Research
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
BMYPositive Net Change JNJPositive Net Change ADMAPositive Net Change TSVTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
by Zacks Equity Research
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
ADMAPositive Net Change FGENNegative Net Change OCGNNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
by Zacks Equity Research
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
ABBVPositive Net Change ADMAPositive Net Change ALDXPositive Net Change FGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
by Zacks Equity Research
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
ANIPPositive Net Change FATENegative Net Change ADMAPositive Net Change GLPGNegative Net Change
biotechnology biotechs medical pharmaceuticals
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
by Zacks Equity Research
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
MRKNo Net Change ADMAPositive Net Change FGENNegative Net Change EFTRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
by Zacks Equity Research
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
BMYPositive Net Change VNDAPositive Net Change VERVPositive Net Change IRONPositive Net Change
biotechnology biotechs pharmaceuticals
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
by Zacks Equity Research
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.
ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change AMLXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
by Zacks Equity Research
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
REGNPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change KODNegative Net Change
biotechnology biotechs medical pharmaceuticals
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
by Zacks Equity Research
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
AZNPositive Net Change RHHBYPositive Net Change MRKNo Net Change GNPXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
by Zacks Equity Research
Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.
LLYPositive Net Change ANIPPositive Net Change ADMAPositive Net Change VERVPositive Net Change
biotechnology medical pharmaceuticals
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
by Zacks Equity Research
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
ACETNegative Net Change ADMAPositive Net Change FGENNegative Net Change EVAXNegative Net Change
biotechnology biotechs medical pharmaceuticals
International Consolidated Airlines Group SA (ICAGY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ICAGYNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
BMYPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change
biotechnology biotechs medical pharmaceuticals
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
by Zacks Equity Research
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change IRONPositive Net Change
biotechnology biotechs pharmaceuticals
Agilent (A) Boosts LSAG Segment With Advanced Dilution System
by Zacks Equity Research
Agilent (A) unveils ADS 2 to enhance workflow efficiency within the laboratory, boosting the LSAG segment.
APositive Net Change AMEPositive Net Change AMATPositive Net Change BLNegative Net Change
biotechnology tech-stocks
Fuel Tech, Inc. (FTEK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FTEKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
by Zacks Equity Research
SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.
IBBPositive Net Change VKTXNegative Net Change XBIPositive Net Change MDGLPositive Net Change
biotechnology
After Golden Cross, J.Jill (JILL)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
JILLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines